Peptide Comparison
Dulaglutide vs Survodutide
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Dulaglutide has stronger documented evidence (FDA-Approved) than Survodutide (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Dulaglutide is the safer pick. Survodutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Dulaglutide | Survodutide | |
|---|---|---|
| Class | GLP-1 receptor agonist | GLP-1/glucagon dual agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | GLP-1 receptor agonist fused to human IgG4 Fc | Dual GLP-1/glucagon receptor activation |
| Route | SC injection | SC injection |
| Half-life | ~5 days | Long-acting weekly |
| Dosage (research) | 0.75 mg SC weekly (Trulicity label starting dose, escalate stepwise to 1.5, 3.0, then label max 4.5 mg weekly for additional glycemic control per AWARD trials) | 0.6-4.8 mg SC weekly |
| Evidence tier | FDA-Approved | Phase 3 |
| Research depth | 311 indexed | 126 indexed |
| Availability | Prescription | Investigational |
| Reported risks | Nausea; diarrhea; pancreatitis risk; thyroid C-cell tumor warning | GI side effects; injection reactions |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Dulaglutide or Survodutide?
Dulaglutide has stronger documented evidence (FDA-Approved) than Survodutide (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Dulaglutide is the safer pick. Survodutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Dulaglutide and Survodutide?
Dulaglutide is classed as GLP-1 receptor agonist; Survodutide is classed as GLP-1/glucagon dual agonist. Reported mechanism: Dulaglutide, GLP-1 receptor agonist fused to human IgG4 Fc; Survodutide, Dual GLP-1/glucagon receptor activation. Reported half-life: Dulaglutide, ~5 days; Survodutide, Long-acting weekly. Routes in published studies: Dulaglutide, SC injection; Survodutide, SC injection.
Which has stronger evidence, Dulaglutide or Survodutide?
Dulaglutide has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Dulaglutide is graded FDA-Approved, with 41 cited sources on its reference page and 311 indexed studies. Survodutide is graded Phase 3, with 33 cited sources on its reference page and 126 indexed studies.
Which is more accessible, Dulaglutide or Survodutide?
Dulaglutide is FDA-approved and Survodutide is not. Catalog status: Dulaglutide, Prescription; Survodutide, Investigational.
Are Dulaglutide and Survodutide ever combined?
Dulaglutide and Survodutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…